ETF Set to Benefit as Vertex Kidney Drug Cuts UPCR 52% in Phase 3 Trial
Vertex’s Phase 3 RAINIER trial of povetacicept in immunoglobulin A nephropathy delivered a 52% reduction in urine protein-to-creatinine ratio at Week 36 and a 49.8% placebo-adjusted drop, with 85.1% of patients resolving hematuria. Pacer S&P 500 Quality FCF R&D Leaders ETF’s 3.43% weighting in Vertex could drive gains upon FDA review completion.
1. Phase III RAINIER Trial Results
Vertex’s ongoing Phase III RAINIER trial of povetacicept in immunoglobulin A nephropathy met its primary endpoint with a 52% reduction in urine protein-to-creatinine ratio at Week 36 and a 49.8% decrease compared to placebo. Additionally, 85.1% of patients with baseline hematuria achieved complete resolution and serum galactose-deficient IgA1 levels fell by 77.4%.
2. FDA Review and Timeline
The Food and Drug Administration has granted a rolling review for povetacicept’s Biologics License Application, with the company planning to finalize its submission by the end of March. Analysts anticipate a priority review under the voucher program and potential approval by year-end, paving the way for market entry in 2027 pending reimbursement.
3. ETF Exposure and Potential Impact
Pacer S&P 500 Quality FCF & R&D Leaders ETF holds a 3.43% position in Vertex, making povetacicept’s trial success a modest catalyst for fund performance. This weighting could translate into gains upon favorable FDA decision, though overall impact is tempered by diversified holdings.